Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003195 · ClinicalTrials.gov registry record · Phase 2
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003195 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00003195, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of total-body irradiation, busulfan, and interferon alfa followed by peripheral stem cell or bone marrow transplantation in treating patients with multiple myeloma.
Interventions
- RADIATION radiation therapy
- PROCEDURE peripheral blood stem cell transplantation
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-12 |
| Est. Completion | 2000-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003195
The ClinicalTrials.gov registry entry for NCT00003195 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which radiation therapy is the first listed.
NCT00003195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003195 about?
NCT00003195 is a clinical study titled "Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectivenes...
What is the current status of trial NCT00003195?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-12. Estimated completion is 2000-11.
What interventions are being tested in trial NCT00003195?
The interventions under investigation include: radiation therapy (RADIATION), peripheral blood stem cell transplantation (PROCEDURE), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003195?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.